Mianserin is an atypical antidepressant of the noradrenergic and specific serotonergic antidepressant (NaSSA) class. It has properties that are virtually identical to mirtazapine except with a lower propensity for causing weight gain.[1] It also, like mirtazapine, inhibits the reuptake of noradrenaline.[2] Unlike with mirtazapine, however, mianserin's propensity for causing agranulocytosis is considered so great that regular blood counts are required for all patients receiving it.[3]
↑"Side effects of mianserin". NPS MedicineWise. Strawberry Hills, Australia: National Prescribing Service. 27 November 2012. Retrieved 10 August 2014.
↑Whiskey, E; Taylor, D (August 2013). "A review of the adverse effects and safety of noradrenergic antidepressants.". Journal of Psychopharmacology27 (8): 732–9. PMID23784737. doi:10.1177/0269881113492027.
↑Joint Formulary Committee (2013). British National Formulary (BNF) 65 (65 ed.). London, UK: Pharmaceutical Press. p. 247. ISBN978-0-85-711084-8.